- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07342608
심실사이중격에 삽입하기 위해 최적화된 LINEA 심장 박동 리드의 안전성과 성능 (STARLIGHT)
심실사이중격에 삽입되도록 최적화된 LINEA 심장 박동 리드의 안전성과 성능
The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.
연구 개요
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Antoine Guihard
- 전화번호: +33 1 46 01 33 20
- 이메일: antoine.guihard@cf.microport.com
연구 장소
-
-
-
Ghent, 벨기에
- 모병
- Ghent University Hospital
-
연락하다:
- Jan De Pooter
- 이메일: jadpoote.depooter@ugent.be
-
-
-
-
-
Girona, 스페인
- 모병
- Hospital Universitari de Girona Doctor Josep Trueta
-
연락하다:
- María Emilce Trucco
- 이메일: metrucco.girona.ics@gencat.cat
-
Granada, 스페인
- 모병
- Hospital Universitario Virgen de las Nieves
-
연락하다:
- Manuel Molina
- 이메일: manuel.molina.lerma@gmail.com
-
Valencia, 스페인
- 모병
- Hospital Universitari i Politècnic La Fe
-
연락하다:
- Óscar Cano
- 이메일: oscape13@hotmail.com
-
-
-
-
-
Novara, 이탈리아
- 모병
- Ospedale Maggiore della Carità - AO Univ.
-
연락하다:
- Gabriele Dell'Era
- 이메일: gabriele.dellera@maggioreosp.novara.it
-
Pisa, 이탈리아
- 모병
- Ospedale San Cataldo CNR - Fond. Toscana G. Monasterio
-
연락하다:
- Gianluca Mirizzi
- 이메일: gmirizzi@ftgm.it
-
-
-
-
-
Coimbra, 포르투갈
- 모병
- ULS de Coimbra
-
연락하다:
- João Ferreira
- 이메일: joaoaferreira29@gmail.com
-
Lisbon, 포르투갈
- 모병
- ULS Santa Maria
-
연락하다:
- Nelson Cunha
- 이메일: nelsoncunha@campus.ul.pt
-
-
-
-
-
Annecy, 프랑스
- 모병
- Centre Hospitalier Annecy Genevois
-
연락하다:
- Pierre Frey
- 이메일: pfrey@ch-annecygenevois.fr
-
Clermont-Ferrand, 프랑스
- 모병
- CHU Clermont-Ferrand
-
연락하다:
- Pierre-Antoine Catalan
- 이메일: pacatalan@chu-clermontferrand.fr
-
Grenoble, 프랑스
- 모병
- CHU Grenoble
-
연락하다:
- Adrien Carabelli
- 이메일: acarabelli@chu-grenoble.fr
-
Montpellier, 프랑스
- 모병
- Clinique du Millénaire
-
연락하다:
- Nicolas Clémenty
- 이메일: nicolas.clementy@gmail.com
-
Rouen, 프랑스
- 모병
- CHU Rouen Hôpital Charles Nicolle
-
연락하다:
- Raphaël Al Hamoud
- 이메일: raphael.al-hamoud@chu-rouen.fr
-
Tours, 프랑스
- 모병
- Hôpital Trousseau
-
연락하다:
- Arnaud Bisson
- 이메일: a.bisson@chu-tours.fr
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria (phase I and II):
- Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
- Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM
- Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area
- Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated
Exclusion criteria (phase I and II):
- Patient planned for a device upgrade, or a device or a lead replacement
- Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy
- Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
- Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
- Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
- Patient with a life expectancy of less than 2 years
- Minor age patient (i.e. under 18 years of age)
- Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
- Non-menopausal women
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: LINEA 심장 페이싱 리드
|
Use of LINEA cardiac pacing lead and delivery catheter for implantation of pacemaker |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
LINEA lead complication free rate at 3 months
기간: 3 months after implantation
|
Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
3 months after implantation
|
|
LINEA lead pacing threshold amplitude at 3 months
기간: 3 months after implantation
|
Mean ventricular pacing threshold amplitude |
3 months after implantation
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Success rate of LINEA lead minimum sensed amplitude
기간: 3 months after implantation
|
Proportion of patients with minimum sensed amplitude ≥ 5 mV |
3 months after implantation
|
|
General performances of LINEA lead
기간: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
Pacing threshold amplitude, impedance and minimum sensed amplitude obtained with the LINEA lead at each patient's visit. LBB pacing threshold amplitude obtained with the LINEA lead during implantation, as well as the chronaxie measurement |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the LINEA lead
기간: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
LINEA lead complication free rate over time, calculated based on number of Adverse Events and Device Deficiencies related to the lead |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the FLEXIGO delivery catheter and the FLEXIGO slitter
기간: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
FLEXIGO catheter complication free rate, calculated based on number of Adverse Events and Device Deficiencies related to the catheter or the slitter |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
LINEA lead implantation success rates
기간: Implantation
|
Proportion of LINEA leads implanted in the interventricular septum and meeting or not LBBAP criteria |
Implantation
|
|
Lead and delivery catheter implantation time
기간: Implantation
|
Total procedural time and total fluoroscopic time of each implantation |
Implantation
|
|
LINEA lead and FLEXIGO delivery catheter and slitter implantation usability
기간: Implantation
|
Handling scores based on a specific questionnaire (scale Very poor/Poor/Acceptable/Good/Very good) |
Implantation
|
|
Right Ventricular Autothreshold performances
기간: 3 months after implantation
|
- Accuracy - Comparison between the manual ventricular pacing threshold performed by a physician and the in-clinic ventricular pacing threshold provided by the RVAT function at the same pulse width and during the same on-site patient's visit |
3 months after implantation
|
|
Evolution of LBBAP capture over time
기간: 18 months after implantation
|
- LBBAP capture evolution with analyses of ECGs (i.e. V6 R-wave peak time and V6-V1 interpeak interval) and LBBAP criteria collected |
18 months after implantation
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Early outcome - Absence of Unanticipated Serious Adverse Device Effect (USADE) related to LINEA lead
기간: 1 month after implantation
|
Proportion of patients free from USADE. Any event caused by use of the LINEA lead or any accessory packaged with the lead, will be considered as an ADE related to the LINEA lead. The endpoint evaluation will be based on an independent safety events adjudication from a Clinical Events Committee (CEC), based on investigational site reporting |
1 month after implantation
|
|
Early outcome - LINEA lead pacing threshold amplitude at 1 month
기간: 1 month after implantation
|
Mean ventricular pacing threshold amplitude |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
기간: 1 month after implantation
|
- Implantation success rate - Proportion of LINEA lead successfully implanted at the interventricular septum and fulfilling or not LBBAP success criteria according to the operator's decision |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
기간: 1 month after implantation
|
- Short term electrical performances variation - Pacing threshold variation between implantation and 1 month, and electrical performances of the LINEA lead (pacing threshold, impedance and minimum sensed amplitude) |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
기간: 1 month after implantation
|
- Complication free rate - Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
1 month after implantation
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .